| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Division of Cardiovascular and Interventional Radiology, The Russell H. Morgan Department of Radiology [J-F. H. G., C. M.], Department of Biological Chemistry [Y. H. K., P. L. P.], and Department of Pathology [M. S. T.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2185
Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitorof cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.
This article has been cited by other articles:
|
|
 |
|
  M. Vali, J. A. Vossen, M. Buijs, J. M. Engles, E. Liapi, V. P. Ventura, A. Khwaja, O. Acha-Ngwodo, G. Shanmugasundaram, L. Syed, et al. Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 32 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Wong, D. S.A. Nuyten, A. Regev, M. Lin, A. S. Adler, E. Segal, M. J. van de Vijver, and H. Y. Chang Revealing Targeted Therapy for Human Cancer by Gene Module Maps Cancer Res., January 15, 2008; 68(2): 369 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim, J.-H. Yoon, J.-M. Jeong, G.-J. Cheon, T.-S. Lee, J.-I. Yang, S.-C. Park, and H.-S. Lee Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2554 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Neuzil, M. Tomasetti, Y. Zhao, L.-F. Dong, M. Birringer, X.-F. Wang, P. Low, K. Wu, B. A. Salvatore, and S. J. Ralph Vitamin E Analogs, a Novel Group of "Mitocans," as Anticancer Agents: The Importance of Being Redox-Silent Mol. Pharmacol., May 1, 2007; 71(5): 1185 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Koukourakis, A. Giatromanolaki, A. L. Harris, and E. Sivridis Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma Cancer Res., January 15, 2006; 66(2): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Isidoro, E. Casado, A. Redondo, P. Acebo, E. Espinosa, A. M. Alonso, P. Cejas, D. Hardisson, J. A. Fresno Vara, C. Belda-Iniesta, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis Carcinogenesis, December 1, 2005; 26(12): 2095 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-h. Xu, H. Pelicano, Y. Zhou, J. S. Carew, L. Feng, K. N. Bhalla, M. J. Keating, and P. Huang Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia Cancer Res., January 15, 2005; 65(2): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gottschalk, N. Anderson, C. Hainz, S. G. Eckhardt, and N. J. Serkova Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells Clin. Cancer Res., October 1, 2004; 10(19): 6661 - 6668. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
